DK2528621T3 - Modificerede tuberkuloseantigener - Google Patents

Modificerede tuberkuloseantigener

Info

Publication number
DK2528621T3
DK2528621T3 DK11700859.9T DK11700859T DK2528621T3 DK 2528621 T3 DK2528621 T3 DK 2528621T3 DK 11700859 T DK11700859 T DK 11700859T DK 2528621 T3 DK2528621 T3 DK 2528621T3
Authority
DK
Denmark
Prior art keywords
modified
tuberculosis antigens
tuberculosis
antigens
modified tuberculosis
Prior art date
Application number
DK11700859.9T
Other languages
Danish (da)
English (en)
Inventor
Normand Blais
James Brown
Anne-Marie Gelinas
Pascal Mettens
Dennis Murphy
Original Assignee
Glaxosmithkline Biologicals Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biologicals Sa
Application granted granted Critical
Publication of DK2528621T3 publication Critical patent/DK2528621T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK11700859.9T 2010-01-27 2011-01-27 Modificerede tuberkuloseantigener DK2528621T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29871010P 2010-01-27 2010-01-27
PCT/EP2011/051158 WO2011092253A1 (en) 2010-01-27 2011-01-27 Modified tuberculosis antigens

Publications (1)

Publication Number Publication Date
DK2528621T3 true DK2528621T3 (da) 2017-01-02

Family

ID=44318698

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11700859.9T DK2528621T3 (da) 2010-01-27 2011-01-27 Modificerede tuberkuloseantigener

Country Status (25)

Country Link
US (2) US8932600B2 (https=)
EP (1) EP2528621B1 (https=)
JP (2) JP6010463B2 (https=)
KR (1) KR20120129927A (https=)
CN (1) CN102869372B (https=)
AU (1) AU2011209399B2 (https=)
BR (1) BR112012018669A2 (https=)
CA (1) CA2786969C (https=)
CO (1) CO6650338A2 (https=)
CY (1) CY1119518T1 (https=)
DK (1) DK2528621T3 (https=)
EA (1) EA201290590A1 (https=)
ES (1) ES2614266T3 (https=)
HR (1) HRP20161608T1 (https=)
HU (1) HUE031184T2 (https=)
LT (1) LT2528621T (https=)
MX (1) MX2012008790A (https=)
MY (1) MY156697A (https=)
PH (1) PH12012501550A1 (https=)
PL (1) PL2528621T3 (https=)
PT (1) PT2528621T (https=)
SG (1) SG182573A1 (https=)
SI (1) SI2528621T1 (https=)
UA (1) UA110103C2 (https=)
WO (1) WO2011092253A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
BR112012018669A2 (pt) * 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
ES2925950T3 (es) 2013-06-25 2022-10-20 Int Aids Vaccine Initiative Inc Composiciones para la tuberculosis y procedimientos de uso de las mismas
US10857219B2 (en) 2014-03-28 2020-12-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN105675863B (zh) * 2016-02-17 2017-10-20 遵义医学院附属医院 一组耐多药结核病诊断标志物及其用途
AU2017285424B2 (en) 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
CN109966170B (zh) * 2018-02-13 2022-04-15 深圳高尚科美生物科技有限公司 包含生物大分子的柔性脂质体化妆品及其制备方法
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
EP4192429A4 (en) * 2020-08-05 2024-10-09 The Administrators of The Tulane Educational Fund METHOD FOR DETECTING TB IN BODY FLUID SAMPLES
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1786412A (en) * 1929-11-20 1930-12-23 American Telephone & Telegraph Shielding arrangement
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
AU7258491A (en) * 1990-02-09 1991-09-03 E.I. Du Pont De Nemours And Company Htlv envelope antigenic segment
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5551622A (en) 1994-07-13 1996-09-03 Yoon; Inbae Surgical stapler
AT402926B (de) 1994-12-05 1997-09-25 Hafslund Nycomed Pharma Heterocyclische amide, verfahren zu ihrer herstellung und verwendung
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
WO1996038591A1 (en) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. IMPROVED METHOD FOR OBTAINING FULL-LENGTH cDNA SEQUENCES
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
CA2230927A1 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU727602B2 (en) 1995-09-01 2000-12-14 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
BR9712298A (pt) 1996-10-11 2000-10-24 Corixa Corp Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
US6350456B1 (en) 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6544522B1 (en) 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6627198B2 (en) 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
CZ298364B6 (cs) 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
PL202844B1 (pl) * 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
EP1229931A4 (en) * 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
US7300998B2 (en) 2002-02-14 2007-11-27 Mitsui Chemicals, Inc. Polyester resin and catalyst for polyester production, process for producing polyester resin with the catalyst, polyester resin obtained with the catalyst, and hollow molded container comprising the polyester resins
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
KR20050010040A (ko) * 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
US7205259B2 (en) 2002-07-26 2007-04-17 Kimberly-Clark Worldwide, Inc. Absorbent binder desiccant composition and articles incorporating it
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US7301098B2 (en) 2005-01-19 2007-11-27 Panduit Corp. Communication channels with suppression cores
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
WO2006117538A2 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
PT1880008E (pt) 2005-05-03 2015-08-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada
JP4468858B2 (ja) 2005-06-01 2010-05-26 オリンパスイメージング株式会社 データ符号化装置、データ符号化方法、プログラム
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7296798B2 (en) 2006-01-31 2007-11-20 Matt Overfield Gameboard, games played on board and methods of play requiring strategy and luck
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
GB0622282D0 (en) * 2006-11-08 2006-12-20 Novartis Ag Quality control methods
PL2137210T3 (pl) * 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
GB0716070D0 (en) * 2007-08-17 2007-09-26 Fusion Antibodies Ltd Diagnostic method and kit
US7670609B2 (en) * 2007-11-27 2010-03-02 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease
FR2933552B1 (fr) 2008-07-04 2014-10-10 Centre Nat Rech Scient Circuit d'amplification d'un signal representant une variation de resistance d'une resistance variable et capteur correspondant
AU2009273130B2 (en) 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
MX2011011186A (es) 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
CA2768777C (en) 2009-07-21 2017-11-28 Cooper Technologies Company Interfacing a light emitting diode (led) module to a heat sink assembly, a light reflector and electrical circuits
BR112012018669A2 (pt) * 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
US9119754B2 (en) 2011-10-08 2015-09-01 Michael Dennis Mattress overlay system with positionally adjustable, lateral ramp-wedge bolster structure
US9051890B2 (en) 2013-10-28 2015-06-09 Ford Global Technologies, Llc Method for estimating charge air cooler condensation storage with an intake oxygen sensor
US9903268B2 (en) 2015-04-02 2018-02-27 Ford Global Technologies, Llc Internal combustion engine with two-stage supercharging capability and with exhaust-gas aftertreatment arrangement, and method for operating an internal combustion engine
US9810514B2 (en) 2015-09-08 2017-11-07 Deufol Sunman Inc. Ammunition carrier consumer package

Also Published As

Publication number Publication date
CA2786969A1 (en) 2011-08-04
JP6503309B2 (ja) 2019-04-17
PH12012501550A1 (en) 2012-10-22
EP2528621A1 (en) 2012-12-05
CO6650338A2 (es) 2013-04-15
LT2528621T (lt) 2016-12-12
AU2011209399A1 (en) 2012-08-23
JP6010463B2 (ja) 2016-10-19
EA201290590A1 (ru) 2013-03-29
MY156697A (en) 2016-03-15
SG182573A1 (en) 2012-08-30
CN102869372B (zh) 2016-01-20
US20150093414A1 (en) 2015-04-02
ES2614266T3 (es) 2017-05-30
UA110103C2 (uk) 2015-11-25
SI2528621T1 (sl) 2017-01-31
US8932600B2 (en) 2015-01-13
MX2012008790A (es) 2012-08-17
US9200044B2 (en) 2015-12-01
US20120294882A1 (en) 2012-11-22
PL2528621T3 (pl) 2017-07-31
EP2528621B1 (en) 2016-09-21
BR112012018669A2 (pt) 2017-09-05
AU2011209399B2 (en) 2014-04-10
HRP20161608T1 (hr) 2017-01-13
PT2528621T (pt) 2016-12-20
KR20120129927A (ko) 2012-11-28
JP2013517783A (ja) 2013-05-20
WO2011092253A1 (en) 2011-08-04
CN102869372A (zh) 2013-01-09
CA2786969C (en) 2018-07-24
CY1119518T1 (el) 2018-03-07
JP2016166193A (ja) 2016-09-15
HUE031184T2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
FR23C1023I2 (fr) Anticorps anti-il-36r
DK2528621T3 (da) Modificerede tuberkuloseantigener
DK3275892T3 (da) Præfusions-rsv-f-antigener
BR112012030311A2 (pt) anticorpo
HUE038962T2 (hu) DLL3-ellenes antitest
IL231777B (en) Antibodies against tl1a and uses thereof
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
EP2629796A4 (en) ANTIBODY
PT2552242E (pt) Resumo
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
DK2616465T3 (da) Triazin-oxadiazoler
DE10170954T8 (de) Mikrowellendruckgarer
CO6791565A2 (es) Anticuerpos anti-notch1
HUE050858T2 (hu) VLA-4 ellenes antitestek
DE112011101226A5 (de) Linearwegmesssystem
EP2646037A4 (en) INHIBITION OF HISTONES
DK2448659T3 (da) Rotorskive
EP2441726A4 (en) LIFT
DK2447426T3 (da) Vaske-WC
DE102010035554B8 (de) Fußtüröffner
DE102010019119B8 (de) Cuttermesser
DE112011101229A5 (de) Geteiltes Schwungrad
CO6841994A2 (es) Anticuerpos
BR112013014731A2 (pt) tamavidina modificada